Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. (Nasdaq: ARVN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat debilitating and life-threatening diseases through the degradation of disease-causing proteins. The company's proprietary PROTAC® Discovery Engine platform creates Proteolysis-Targeting Chimeras (PROTACs), which leverage the cell's natural protein disposal system to target and degrade specific proteins involved in various diseases.
Founded on groundbreaking research from Yale University by Dr. Craig Crews, Arvinas is at the forefront of transforming protein degradation into novel therapeutic strategies. Their lead candidates include bavdegalutamide (ARV-110) and ARV-766, aimed at treating metastatic castration-resistant prostate cancer, and vepdegestrant (ARV-471), which targets estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Recent achievements highlight Arvinas' robust pipeline and strategic partnerships. In collaboration with Pfizer, vepdegestrant is undergoing Phase 3 trials, showing promising clinical activity and safety in heavily pre-treated breast cancer patients. The company has also initiated a strategic license agreement with Novartis for the global development and commercialization of ARV-766, affirming its potential as a first-in-class treatment for prostate cancer.
Financially, Arvinas maintains a strong position with sufficient resources to fund operations into 2027, bolstered by strategic collaborations and revenue from ongoing license agreements. The company's focus on expanding its clinical trials and exploring new combination therapies positions it for significant impact in oncology and beyond.
For the latest updates on Arvinas' developments and clinical trials, visit their website at www.arvinas.com.
Arvinas (ARVN) and Pfizer (PFE) announced preliminary Phase 1b data from the TACTIVE-U sub-study evaluating vepdegestrant in combination with abemaciclib for breast cancer treatment. The study showed a clinical benefit rate of 62.5% and an overall response rate of 26.7% in patients previously treated with CDK4/6 inhibitors.
The trial demonstrated a tolerable safety profile using abemaciclib 150mg twice daily with vepdegestrant 200mg once daily. No significant drug-drug interactions were observed. The most common side effects included diarrhea, nausea, and fatigue, with no grade 4 or 5 adverse events reported.
As of August 30, 2024, five patients remained on study treatment. The results support the ongoing Phase 2 portion of the study.
Arvinas (Nasdaq: ARVN), a clinical-stage biotech company focused on targeted protein degradation, announced its participation in the Piper Sandler 36th Annual Healthcare Conference. Chief Medical Officer Noah Berkowitz, M.D., Ph.D., and Chief Financial Officer Andrew Saik will engage in a fireside chat on Tuesday, December 3 at 2:30 p.m. ET in New York. The presentation will be accessible via live audio webcast on the company's website under the Events and Presentations section.
Arvinas announced three poster presentations for vepdegestrant at the 2024 San Antonio Breast Cancer Symposium (SABCS). Vepdegestrant, a PROTAC estrogen receptor degrader, is being jointly developed with Pfizer for treating ER+/HER2- breast cancer. The presentations will cover: combination therapy with palbociclib in CDK4/6 inhibitor-resistant models, preliminary Phase 1b results of vepdegestrant plus abemaciclib in advanced breast cancer, and CYP3A4-mediated drug interaction risks when combined with CDK4/6 inhibitors and everolimus. The posters will be presented on December 12, 2024.
Arvinas (NASDAQ: ARVN), a clinical-stage biotech company focused on targeted protein degradation, has announced its participation in two major investor conferences. The company will be present at the Guggenheim Securities Healthcare Innovation Conference on November 13, where Chief Medical Officer Noah Berkowitz and Chief Business Officer Randy Teel will join a fireside chat. Additionally, on November 19, Berkowitz and Chief Financial Officer Andrew Saik will participate in a fireside chat at the Jefferies London Healthcare Conference. Live audio webcasts of both presentations will be accessible through the company's website and dedicated links.
Arvinas (ARVN) reported Q3 2024 financial results with revenue of $102.4 million, up from $34.6 million in Q3 2023. The company maintains $1.1 billion in cash and equivalents, expected to fund operations into 2027. Key developments include ongoing enrollment in multiple clinical studies for vepdegestrant in breast cancer, with topline data from VERITAC-2 Phase 3 trial expected in Q4 2024 or Q1 2025. Research and development expenses were $86.9 million, while general and administrative expenses increased to $75.8 million, including a $43.4 million lease termination loss.
Arvinas, a clinical-stage biotechnology company, held its third annual Arvinas Impact Day, a company-wide day of service. Employees from 16 states participated in various volunteer activities across the Greater New Haven area and beyond. The event aligns with Arvinas' core values and aims to make a positive impact in local communities.
Highlights from the day include:
- Save the Sound: Collected over 287 pounds of trash to protect local wildlife and environments
- Boys and Girls Club of Greater New Haven: Beautified indoor and outdoor spaces at two locations
- Friends of East Rock Park: Maintained walking paths by laying crushed stone and cutting back brush
- Employee-Selected Activities: Ranged from food bank support to animal shelters and neighborhood clean-ups
John Houston, Ph.D., Chairperson, CEO, and President at Arvinas, expressed pride in the employees' dedication and enthusiasm in supporting vital community organizations.
Arvinas (Nasdaq: ARVN), a clinical-stage biotechnology company focused on developing targeted protein degradation drugs, has announced its upcoming third quarter 2024 financial results and corporate update webcast. The event is scheduled for Wednesday, October 30, 2024, at 8:00 a.m. ET.
Investors and interested parties can access the live webcast through the 'Events and Presentations' section on the company's investor page. For those unable to attend the live event, a replay will be made available on the Arvinas website following the presentation.
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company specializing in targeted protein degradation, has announced its participation in two upcoming investor conferences:
- The Wells Fargo Healthcare Conference on September 5, 2024, featuring a fireside chat with Ian Taylor, Ph.D., President of R&D, and Randy Teel, Ph.D., Chief Business Officer.
- The Cantor Global Healthcare Conference on September 19, 2024, with Noah Berkowitz, MD, Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, participating in a fireside chat.
Both presentations will be available via live audio webcast on the company's website and through provided links. This engagement with investors highlights Arvinas' commitment to transparency and shareholder communication.
Arvinas (NASDAQ: ARVN) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Completed enrollment in VERITAC-3 Phase 3 trial lead-in for vepdegestrant in first-line ER+/HER2- metastatic breast cancer
- VERITAC-2 Phase 3 trial enrollment completion expected in Q4 2024, with topline data in Q4 2024/Q1 2025
- Received $150 million from Novartis for ARV-766 license and AR-V7 program sale
- Q2 revenue: $76.5 million, up from $54.5 million in Q2 2023
- Cash position: $1.23 billion as of June 30, 2024
- Sufficient funding into 2027
The company continues to advance its PROTAC protein degradation platform across multiple indications.
Arvinas (NASDAQ: ARVN) appoints Andrew Saik as Chief Financial Officer and Treasurer, effective June 24, 2024. Saik, an experienced biopharma finance executive, previously served as CFO at Intercept Pharmaceuticals where he led significant financial restructuring efforts. At Arvinas, he will focus on building financial systems and infrastructure necessary for transitioning to a commercial-stage biotech and managing ongoing clinical-stage programs. In connection with his appointment, Saik received an inducement grant of options to purchase 94,418 shares and a restricted stock unit for 61,409 shares, under Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Arvinas (ARVN)?
What is the market cap of Arvinas (ARVN)?
What does Arvinas, Inc. specialize in?
What are Arvinas' lead product candidates?
What recent partnerships has Arvinas entered?
What financial position does Arvinas hold for its future operations?
What is PROTAC®?
How does vepdegestrant (ARV-471) work?
What are the key achievements of Arvinas recently?
What is the significance of Arvinas' collaboration with Pfizer?
What diseases is Arvinas targeting with its therapies?
Where can I find more information about Arvinas?
